(Q40814966)

24 September 2017

title

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients (English)

1 reference

24 September 2017

Rep MH

1

1 reference

24 September 2017

Schrijver HM

2

1 reference

24 September 2017

van Lopik T

3

1 reference

24 September 2017

Hintzen RQ

4

1 reference

24 September 2017

Roos MT

5

1 reference

24 September 2017

Adèr HJ

6

1 reference

24 September 2017

Polman CH

7

1 reference

24 September 2017

van Lier RA

8

1 reference

24 September 2017

publication date

1 April 1999

1 reference

Journal of Neuroimmunology

24 September 2017

published in

1 reference

24 September 2017

volume

96

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

92-100

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Mechanisms of action of interferon-beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

1 reference

7 January 2021

Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

The Th1/Th2 balance in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Th1 and Th2 cells in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Th-cell modulation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Biological properties of interleukin 10.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Immunotherapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Detection of intracellular cytokines by flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

The role of IL-10 in crossregulation of TH1 and TH2 responses

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Influence of infection on exacerbations of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Recombinant Interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Clinical viral infections and multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Activation of the apoptotic Fas antigen-encoding gene upon influenza virus infection involving spontaneously produced beta-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900271-9

7 January 2021

10.1016/S0165-5728(98)00271-9

Identifiers

DOI

1 reference

24 September 2017

1 reference